Latest Posts › Japan

Share:

The impact of COVID-19 on clinical trials and countermeasure development in Japan

On 19 March 2020, the Ministry of Health, Labour and Welfare of Japan (MHLW) issued a notice announcing a waiver of the statutorily-required waiting period after submitting a request for clinical trial to the MHLW in respect...more

Covid-19 IP Update: Impact on litigation (UPDATED)

Court of Justice of the European Union (CJEU) - The CJEU has announced? temporary changes to its working arrangements. Judicial activity will continue, but priority will be given to those cases that are particularly...more

Japan waives clinical trial waiting period for COVID-19 treatments

On 19 March 2020, the Ministry of Health, Labour and Welfare of Japan (MHLW) issued a notice announcing a waiver of the statutorily-required waiting period after submitting a request for clinical trial to the MHLW in respect...more

Covid-19 IP Update: Impact on litigation (UPDATED)

France - By an implementation regulation issued on 16 March 2020, the Ministry of Justice has declared the closure of the courts, except for criminal and civil emergency services. This measure involves both the suspension of...more

Dr. Frederick Ch’en discusses generic drugs and the changing pharmaceutical landscape in Asia [Video]

Dr. Frederick Ch’en, an IP partner in Hogan Lovells’ Tokyo office, explains the political and demographic changes fueling changes in Japan and throughout Asia, and the practical impact on pharmaceutical companies doing...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide